Clarithromycin for the Treatment of Infections Caused by Nontuberculous

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Status Completed

Clinical Trial Summary

Use of oral clarithromycin for treatment of chronic lung disease due to Mycobacterium avium-intracellulare and other non-tuberculous Mycobacteria

Oral clarithromycin for treatment of MAC and other nontuberculous mycobacteria in adults with clinical history ;

NCT number	NCT00600769
Study type	Interventional
Source	The University of Texas Health Science Center at Tyler
Contact
Status	Completed
Phase	Phase 4
Start date	January 1991
Completion date	May 18, 2017

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05192057` - Hypertonic Saline Inhalation for Mycobacterium Avium Complex Pulmonary Disease	Phase 4
Withdrawn	`NCT01719042` - Improving Tolerance of Treatment of Pulmonary MAC Infections	Phase 2
Recruiting	`NCT03236987` - CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections	Phase 3
Recruiting	`NCT04287049` - A Study of Standard Drugs for Mycobacterium Avium Complex	Phase 2
Recruiting	`NCT03672630` - Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease	Phase 2/Phase 3
Completed	`NCT04685720` - A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients	N/A
Terminated	`NCT04553406` - Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease	Phase 2
Completed	`NCT00598962` - Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease	Phase 4
Recruiting	`NCT05824988` - Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease
Recruiting	`NCT02968212` - Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)	Phase 2